Viking Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VKTX research report →
Range $34 – $120
Price Chart
About the company
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß).
- CEO
- Brian Lian
- IPO
- 2015
- Employees
- 65
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on VKTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.16B
- P/E
- -4.98
- Fwd P/E
- 14.88
- PEG
- 0.07
- P/S
- 0.00
- P/B
- 5.39
- EV/EBITDA
- -4.79
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -117.35%
- ROIC
- -76.91%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-431,000+0.0%
- Op Income
- $-393,342,000
- Net Income
- $-359,639,000-227.1%
- EPS
- $-3.19-215.8%
- OCF Growth
- -217.4%
- FCF Growth
- -217.4%
- 52W High
- $43.10
- 52W Low
- $23.82
- 50D MA
- $28.77
- 200D MA
- $32.11
- Beta
- 0.65
- RSI (14)
- 41
- Avg Volume
- 5.27M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Viking reported a wider Q3 loss on sharply higher R&D spend, while saying its Phase III obesity programs remain on track and its cash runway was extended by a $575 million financing.· October 28, 2026
- Both VANQUISH Phase III subcutaneous trials are fully enrolled and advancing toward completion; first patients are expected into the extension period in early 2027.
- The oral VK2735 SUNRISE Phase III program has started, with management emphasizing lower tablet burden, economic viability, and the chance to be the first oral dual GLP-1/GIP agonist to market.
- The company reported positive maintenance-study data showing subjects maintained most of their weight loss on every-other-week or monthly dosing, supporting a less-frequent maintenance strategy.
- Viking ended Q3 with $960 million in cash, cash equivalents and short-term investments after raising about $575 million in gross proceeds from stock and convertible note offerings.
- Management said the amylin program VK3019 should finish the current single-ascending-dose study by year-end and move to a multiple-ascending-dose study in Q1 2027.
For Q3 2026, research and development expense was $166.8 million versus $90 million a year ago, general and administrative expense was $20.3 million versus $8.6 million, and net loss was $183.2 million, or $1.55 per share, versus a net loss of $90.8 million, or $0.81 per share. For the first nine months of 2026, R&D expense was $432.7 million versus $191.5 million, G&A expense was $51.1 million versus $37.1 million, and net loss was $469.5 million, or $4.03 per share, versus a net loss of $202 million, or $1.80 per share. Cash, cash equivalents and short-term investments were $960 million at September 30, 2026, up from $706 million at December 31, 2025, and management said the recent financing produced about $575 million in gross proceeds and about $550 million in net proceeds. The company did not provide revenue guidance because it remains pre-commercial; forward-looking commentary focused on pipeline timing, including VANQUISH completion, SUNRISE execution, 2027 maintenance-study data, and completion of the VK3019 SAD study by year-end.
Brian Lian struck an optimistic, execution-focused tone, saying the company made important progress across multiple programs and is advancing both injectable and oral VK2735 in parallel. He repeatedly highlighted differentiation from having two formulations, the possibility of less-frequent dosing, and the maintenance data as evidence for flexible long-term weight-management strategies. He also said the recently raised capital substantially increases runway and supports ongoing development plus commercial preparation.
Greg Zante focused on the cost step-up tied to late-stage development and infrastructure buildout. He cited Q3 R&D of $166.8 million and G&A of $20.3 million, with the nine-month figures at $432.7 million and $51.1 million, respectively, and said the company had $960 million in cash, cash equivalents and short-term investments at quarter end. On capital usage, he suggested average cash usage of around $100 million per quarter, with SG&A fairly flat in the near term and possibly picking up later as commercialization approaches.
Analysts pressed on comparability versus tirzepatide, commercial differentiation, the rationale for the tighter oral dose range, and whether maintenance data could support label language. Management cautioned against cross-trial comparisons, saying the data will stand on its own, and pointed to differentiation from having both subcutaneous and oral formulations plus weekly, every-other-week, and monthly options. On maintenance labeling, Brian Lian said Viking thinks extension studies could support label language, but timing and whether the data goes into the initial filing versus a later supplement remain TBD; he also said VANQUISH discontinuation rates are tracking expectations.
The main positive case is that Viking now has two large Phase III obesity programs underway for VK2735, with both subcutaneous trials fully enrolled and the oral program newly initiated. Management also said maintenance data showed meaningful weight-loss retention with less frequent dosing and no meaningful tolerability difference versus placebo, which could support a differentiated label and commercial story.
The biggest risks are that the company is still pre-revenue while spending remains very high, with Q3 net loss widening to $183.2 million and nine-month net loss to $469.5 million. Management also acknowledged that several important items are still uncertain, including whether maintenance data can make it into an initial filing, how oral maintenance will perform, and what the amylin program will ultimately show in the clinic.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.1%
- Shares Outstanding
- 127.52M
- Float Shares
- 123.79M
of shares held by institutions
472 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 9.98M | ▼ 14.62K |
| Fmr LLC | 9.85M | ▲ 3.51M |
| Blackrock, Inc. | 6.16M | ▼ 24.65K |
| State Street Corp | 5.55M | ▼ 61.27K |
| Vanguard Capital Management LLC | 5.39M | ▲ 340.51K |
| Vanguard Portfolio Management LLC | 4.72M | ▲ 233.65K |
| Two Sigma Investments, LP | 3.94M | ▼ 494.73K |
| Morgan Stanley | 3.58M | ▲ 93.28K |
| Geode Capital Management, LLC | 2.20M | ▲ 105.17K |
| Ameriprise Financial Inc | 2.16M | ▲ 477.34K |
| Two Sigma Advisers, LP | 2.13M | ▲ 574.10K |
| American Century Companies Inc | 1.63M | ▼ 188.28K |
Held by 507 ETFs
Biggest fund positions in VKTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 1, 26 | Kelly-Gemmell Dorothy Elizabeth | other | 40,800 |
| Aug 1, 26 | Kelly-Gemmell Dorothy Elizabeth | other | 6,333 |
| Aug 1, 26 | Kelly-Gemmell Dorothy Elizabeth | other | 0 |
| Jul 28, 26 | Lian Brian | other | 221,667 |
| Jul 29, 26 | Lian Brian | sell | 148,517 |
| Jul 28, 26 | ZANTE GREG | other | 31,667 |
| Jul 29, 26 | ZANTE GREG | sell | 21,217 |
| Jul 28, 26 | Mancini Marianna | other | 31,667 |
| Jul 29, 26 | Mancini Marianna | sell | 18,217 |
| Jun 1, 26 | Chen Hubert C | other | 190,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our VKTX coverage
Recent articles, reports, and earnings notes.

Should You Buy Corxel US Before the SPAC Merger Closes?
Corxel US is a clinical-stage biopharmaceutical company developing oral obesity and cardiometabolic therapies, and it is going public through a merger with Amanat Acquisition Corp. (Nasdaq: AMAN). The deal is expected to close in the first half of 2027, but shareholders should watch the cash raise and redemption math closely because dilution and trust leakage could reshape the setup.

What to Watch as Retension Pharmaceuticals Prices on Nasdaq
Retension Pharmaceuticals Inc. (NASDAQ: RTSN) is expected to list on 2026-10-09, and the company has not disclosed a price range. The IPO is priced, with 3,300,000 shares offered and a disclosed market cap of $41.25 million. The setup is straightforward: shareholders should watch whether RTN-001’s Phase 2b data can support a larger hypertension story, but the stock still carries classic single-asset biotech risk.

Vogenx Inc IPO Preview: Metabolic Biotech Meets Cash Runway Risk
Vogenx Inc Common Stock is expected to list on NASDAQ on 2026-08-12, but the price range has not been disclosed. The company is a clinical-stage biopharma name focused on metabolic disorders, including post-bariatric hypoglycemia and gastroparesis. The setup favors investors who want an early-stage catalyst story, but shareholders should watch the capital needs and clinical risk closely.
Want a deeper read on VKTX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Viking Therapeutics Eyes 2029 Obesity Drug Launch, Tests Less-Frequent Dosing
marketbeat.com · Nov 18
Viking Therapeutics, Inc. (VKTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
Have $1,000? This Beaten-Down Biotech Has 4 Phase 3 Obesity Trials Underway.
fool.com · Nov 18
Viking: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 17
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
gurufocus.com · Nov 15
Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026
prnewswire.com · Nov 15
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
zacks.com · Nov 13
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
fool.com · Nov 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.